Mitoxantrone as a potential therapy for primary progressive multiple sclerosis-Reference-Cited by-同舟云学术

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Published:2004-05 Issue:3_suppl Volume:10 Page:S58-S61
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Stüve Olaf¹,Kita Mariko²,Pelletier Daniel¹,Fox Robert J³,Stone Jerome¹,Goodkin Donald E⁴,Zamvil Scott S⁵

Affiliation:

1. Department of Neurology, University of California, San Francisco, CA, USA

2. Virginia Mason Multiple Sclerosis Center, Seattle, WA, USA

3. Department of Neurology, Mellen Center for MS, Cleveland Clinic Foundation, Cleveland, OH, USA

4. Multiple Sclerosis Therapeutics, Biogen, Cambridge, MA, USA

5. Department of Neurology, University of California, San Francisco, CA, USA, zamvil@ucsf.neuroimmunol.org

Abstract

Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North A merica for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo -controlled phase 2 trial will be outlined in this article.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1191/1352458504ms1032oa

Reference35 articles.

1. Defining the clinical course of multiple sclerosis: Results of an international survey

2. COURSE AND PROGNOSIS OF MULTIPLE SCLEROSIS ASSESSED BY THE COMPUTERIZED DATA PROCESSING OF 349 PATIENTS

3. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I

4. Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study

5. THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis;Expert Opinion on Therapeutic Targets;2023-05-04

2. Investigation of miR-146a Expression Profiles in Fecal Samples of Patients With Multiple Sclerosis for Early Diagnosis and Treatment;Neurological Sciences and Neurophysiology;2023

3. Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?;CNS Drugs;2022-09-30

4. Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics;Journal of Neuroinflammation;2022-02-10

5. Host–Guest Complexation of Cucurbit[7]Uril and Cucurbit[8]Uril with the Antineoplastic and Multiple Sclerosis Agent Mitoxantrone (Novantrone);The Journal of Physical Chemistry A;2021-01-08